Core Laboratories (CLB) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
18 Jan, 2026Executive summary
Q3 2024 revenue was $134.4 million, up 3% sequentially and 7% year-over-year, with operating income of $19.8 million and EPS of $0.25, both up over 27% year-over-year, driven by international growth and technology deployment despite geopolitical and weather-related headwinds.
Free cash flow for Q3 was $10.4 million, prioritized for debt reduction, lowering net debt by $11.8 million in Q3 and $30.4 million year-to-date, achieving the lowest leverage ratio in six years.
Both Reservoir Description and Production Enhancement segments posted 3% sequential revenue growth, with international sales offsetting U.S. market softness and Gulf of Mexico project delays.
Operating margins improved to 14–15%, with gross margin at 21% and return on invested capital at 8.6%.
Insurance recoveries of $5.6 million related to a U.K. facility fire offset business interruption and property damage.
Financial highlights
Q3 2024 revenue was $134.4 million, with service revenue at $98.8 million (up 3% sequentially, 6% year-over-year) and product sales at $35.6 million (up 4% sequentially, 10% year-over-year).
Net income attributable to shareholders was $11.7 million for Q3 2024, up 27% year-over-year, with EPS of $0.25.
EBIT ex items was $18.2 million (up 11% sequentially), with EBIT margin at 14%.
Free cash flow for Q3 was $10.4 million; for the first nine months, $27.1 million, a significant year-over-year improvement.
Current ratio improved to 2.48:1, and interest coverage at 6.13.
Outlook and guidance
Q4 2024 revenue projected at $128.5–$135.5 million, operating income $14.8–$17.7 million, and EPS $0.20–$0.25.
Multi-year international recovery expected, driven by underinvestment, energy security, and rising crude demand.
Reservoir Description Q4 revenue expected flat to slightly up; Production Enhancement to see typical seasonal decline.
U.S. land activity to trend lower in Q4 but rebound in 2025; international projects to drive growth.
Continued expansion in large-scale core analyses, reservoir fluids characterization, and carbon capture projects anticipated.
Latest events from Core Laboratories
- Q4 revenue up 7% year-over-year; Q1 2026 guidance: $124–$130M revenue, $0.11–$0.15 EPS.CLB
Q4 20255 Feb 2026 - Q2 2024 delivered higher margins, strong cash flow, and international growth despite U.S. softness.CLB
Q2 20243 Feb 2026 - Full-year growth in revenue and EPS, strong cash flow, and improved leverage amid global risks.CLB
Q4 20249 Jan 2026 - Q1 revenue and profit declined, but free cash flow rose and Q2 guidance signals recovery.CLB
Q1 202524 Dec 2025 - Q2 2025 revenue rose 5% sequentially to $130.2M, with net income up 18% to $10.6M.CLB
Q2 202516 Nov 2025 - Sequential revenue and margin growth, share buybacks, and strong international demand in Q3.CLB
Q3 202524 Oct 2025